prazosin has been researched along with Chronic Disease in 86 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)." | 9.22 | A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. ( Liang, K; Wang, J; Xu, Z; Yan, D, 2016) |
| "To investigate the efficacy and safety of the alpha1-receptor inhibitor terazosin combined with chlormezanone in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)." | 9.14 | [Retrospective analysis of the combined therapy of terazosin with chlormezanone for chronic prostatitis/chronic pelvic pain syndrome]. ( Li, HJ; Li, HZ; Yan, S; Zhang, XY, 2009) |
| "To evaluate the clinical efficacy and safety of dexketoprofen trometamol in the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)." | 9.14 | [Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome]. ( Jiang, MH; Liu, HL; Wu, GC, 2009) |
| "To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome." | 9.11 | Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2004) |
| "Terazosin proved superior to placebo for patients with chronic prostatitis/chronic pelvic pain syndrome who had not received alpha-blockers previously." | 9.10 | Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2003) |
| "Right heart catheterization was performed before and during long-term therapy with prazosin in 27 patients with severe chronic heart failure who underwent serial hemodynamic studies during 3 to 12 weeks of treatment with the drug." | 9.06 | Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "The effects of prazosin therapy were recently evaluated in ambulatory patients with essential hypertension and chronic obstructive pulmonary disease." | 9.06 | Prazosin in hypertensive patients with chronic bronchitis and asthma: a brief report. ( Chodosh, S; Pizzuto, D; Tuck, J, 1989) |
| "The long-term effects of prazosin in chronic congestive heart failure were studied in 10 patients (New York Heart Association class III-IV) in a double-blind cross-over study." | 9.06 | Hemodynamic effects at rest and during exercise in long-term treatment with prazosin in chronic congestive heart failure. ( Koss, A; Sivertssen, E; Westheim, A, 1986) |
| "Ten patients with severe chronic heart failure were given prazosin 5 mg and captopril 25 mg in random order on consecutive days." | 9.05 | Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. ( Coxon, R; Sharpe, DN, 1982) |
| "Long-term treatment of congestive heart failure with prazosin is disputed." | 9.05 | [Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year]. ( Bussmann, WD; Kaltenbach, M; Nadj, M; Reifart, N; Schmidt-Moritz, AD, 1985) |
| "The acute haemodynamic effects of prazosin 5 mg were investigated in 11 patients with severe chronic congestive cardiac failure." | 9.05 | Prazosin in the treatment of severe chronic congestive cardiac failure. ( Clarke, GM; Cope, GD; Hockings, BE; Taylor, RR, 1980) |
| "To investigate the mechanism of pharmacodynamic tolerance reported to occur during prazosin therapy of chronic congestive heart failure, we measured plasma norepinephrine, plasma epinephrine, plasma renin activity (PRA) and plasma aldosterone, as well as hemodynamics in eight patients with chronic congestive heart failure, functional class III and IV (NYHA), before and during 10 weeks of prazosin therapy." | 9.05 | Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. ( Henry, DP; Stein, L; Weinberger, MH, 1981) |
| " In cobalt-induced epilepsy in the rat activity is associated with a cortical NA denervation." | 8.77 | Chronic cobalt-induced epilepsy: noradrenaline ionophoresis and adrenoceptor binding studies in the rat cerebral cortex. ( Bregman, B; Chauvel, P; Le Saux, F; Maurin, Y; Trottier, S, 1985) |
| "Oral prazosin hydrochloride (2-20 mg/day) was administered to 38 patients with chronic congestive heart failure due to ischemic heart disease for 6-18 months." | 7.68 | Prazosin in chronic congestive heart failure due to ischemic heart disease. ( Antani, JA; Antani, NJ; Nanivadekar, AS, 1991) |
| "The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1)." | 7.67 | Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. ( Halvorsen, FJ; Jentoft, H; Vik-Mo, H; Walde, N, 1985) |
| "The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure." | 7.66 | Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure. ( Arnold, S; Brundage, B; Chatterjee, K; Parmley, W; Ports, TA, 1979) |
| "The persistence of the hemodynamic effects of prazosin was studied in 12 patients with chronic congestive heart failure." | 7.66 | Attenuation of prazosin effect on cardiac output in chronic heart failure. ( Arnold, SB; Baughman, RA; Benet, LZ; Chatterjee, K; Parmley, WW; Ports, TA; Williams, RL, 1979) |
| "The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients." | 7.66 | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. ( Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979) |
| "The acute hemodynamic effects of oral prazosin were investigated in 7 patients with chronic refractory heart failure." | 7.66 | Acute and chronic cardiocirculatory effects of oral prazosin in chronic refractory heart failure. ( Fukaya, T; Hayashi, H; Matsui, E; Niwa, T; Oba, M; Okubo, M; Sassa, H, 1980) |
| "In addition to digitalis and diuretics, 10 patients with chronic cardiac failure were treated with prazosin (15 mg/d) over a period of 6 months." | 7.66 | [Prazosin long-term treatment in severe chronic cardiac failure (author's transl)]. ( Bleifeld, W; Hanrath, P; Kuck, KH; Mathey, D; Zehnke, A, 1980) |
| "Twelve patients with severe chronic congestive heart failure (CHF) (NYHA class III and IV) resistant to digitalis and diuretics were treated with the postsynaptic alpha-blocking agent prazosin (PZ) (3 to 20 mg/day)." | 7.66 | Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure. ( Bertel, O; Bühler, FR; Burkart, F, 1981) |
| "To evaluate whether long-term administration of the oral vasodilator, prazosin, in the ambulatory therapy of chronic refractory congestive heart failure (CHF) results in gradual attentuation of its marked salutary peripheral circulatory relaxing actions, 16 coronary heart failure patients receiving chronic prazosin, 16 mg daily, were assessed for the development of vasodilator tolerance for 12 months." | 7.66 | Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. ( Awan, NA; DeMaria, AN; Lee, G; Mason, DT, 1981) |
| "The long-term efficacy of the new oral vasodilator, prazosin (PZ), was evaluated in nine patients with refractory heart failure due to chronic coronary heart disease." | 7.65 | Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn ( Awan, NA; DeMaria, AN; Mason, DT; Maxwell, KS; Miller, RR; Neumann, A, 1977) |
| "Terazosine was effective for the treatment of CPPS." | 6.70 | Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. ( Eroğlu, M; Gül, O; Ozok, U, 2001) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 5.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)." | 5.22 | A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. ( Liang, K; Wang, J; Xu, Z; Yan, D, 2016) |
| "We obtained NIH-CPSI and IIEF-5 scores from 132 chronic prostatitis patients with ED and divided the patients into a control (n = 70) and a treatment group (n = 62), the former treated with oral levofloxacin 0." | 5.16 | [Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction]. ( Chao, WF; Huang, XK; Liang, P; Liu, JW; Wang, L; Wang, QT; Yang, H; Yang, W; Zhou, P, 2012) |
| "To investigate the efficacy and safety of the alpha1-receptor inhibitor terazosin combined with chlormezanone in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)." | 5.14 | [Retrospective analysis of the combined therapy of terazosin with chlormezanone for chronic prostatitis/chronic pelvic pain syndrome]. ( Li, HJ; Li, HZ; Yan, S; Zhang, XY, 2009) |
| "To evaluate the clinical efficacy and safety of dexketoprofen trometamol in the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)." | 5.14 | [Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome]. ( Jiang, MH; Liu, HL; Wu, GC, 2009) |
| "To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome." | 5.11 | Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2004) |
| "Terazosin proved superior to placebo for patients with chronic prostatitis/chronic pelvic pain syndrome who had not received alpha-blockers previously." | 5.10 | Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. ( Cheah, PY; Khor, T; Krieger, JN; Liong, ML; Teh, CL; Yang, JR; Yap, HW; Yuen, KH, 2003) |
| "The effects of prazosin therapy were recently evaluated in ambulatory patients with essential hypertension and chronic obstructive pulmonary disease." | 5.06 | Prazosin in hypertensive patients with chronic bronchitis and asthma: a brief report. ( Chodosh, S; Pizzuto, D; Tuck, J, 1989) |
| "The long-term effects of prazosin in chronic congestive heart failure were studied in 10 patients (New York Heart Association class III-IV) in a double-blind cross-over study." | 5.06 | Hemodynamic effects at rest and during exercise in long-term treatment with prazosin in chronic congestive heart failure. ( Koss, A; Sivertssen, E; Westheim, A, 1986) |
| "Right heart catheterization was performed before and during long-term therapy with prazosin in 27 patients with severe chronic heart failure who underwent serial hemodynamic studies during 3 to 12 weeks of treatment with the drug." | 5.06 | Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "To investigate the mechanism of pharmacodynamic tolerance reported to occur during prazosin therapy of chronic congestive heart failure, we measured plasma norepinephrine, plasma epinephrine, plasma renin activity (PRA) and plasma aldosterone, as well as hemodynamics in eight patients with chronic congestive heart failure, functional class III and IV (NYHA), before and during 10 weeks of prazosin therapy." | 5.05 | Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. ( Henry, DP; Stein, L; Weinberger, MH, 1981) |
| "Ten patients with severe chronic heart failure were given prazosin 5 mg and captopril 25 mg in random order on consecutive days." | 5.05 | Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects. ( Coxon, R; Sharpe, DN, 1982) |
| "The acute haemodynamic effects of prazosin 5 mg were investigated in 11 patients with severe chronic congestive cardiac failure." | 5.05 | Prazosin in the treatment of severe chronic congestive cardiac failure. ( Clarke, GM; Cope, GD; Hockings, BE; Taylor, RR, 1980) |
| "Long-term treatment of congestive heart failure with prazosin is disputed." | 5.05 | [Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year]. ( Bussmann, WD; Kaltenbach, M; Nadj, M; Reifart, N; Schmidt-Moritz, AD, 1985) |
| " In cobalt-induced epilepsy in the rat activity is associated with a cortical NA denervation." | 4.77 | Chronic cobalt-induced epilepsy: noradrenaline ionophoresis and adrenoceptor binding studies in the rat cerebral cortex. ( Bregman, B; Chauvel, P; Le Saux, F; Maurin, Y; Trottier, S, 1985) |
| "Oral prazosin hydrochloride (2-20 mg/day) was administered to 38 patients with chronic congestive heart failure due to ischemic heart disease for 6-18 months." | 3.68 | Prazosin in chronic congestive heart failure due to ischemic heart disease. ( Antani, JA; Antani, NJ; Nanivadekar, AS, 1991) |
| "The purpose of the present study was to find out whether the beneficial effect of prazosin in congestive heart failure persists after 2 and 6 months of treatment and whether the clinical and haemodynamic data obtained correlate with the response to treatment." | 3.67 | [Value of early vasodilator treatment with prazosin in chronic cardiac insufficiency]. ( Aumont, MC; Cohen-Solal, A; Gourgon, R; Le Pailleur, C; Motté, G; Vacheron, A, 1987) |
| "Arginine vasopressin is elevated in congestive heart failure." | 3.67 | Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure. ( Hood, WB; Imai, N; Liang, CS; Sakamoto, S; Sladek, CD; Stone, CK, 1988) |
| "The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1)." | 3.67 | Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. ( Halvorsen, FJ; Jentoft, H; Vik-Mo, H; Walde, N, 1985) |
| "The persistence of the hemodynamic effects of prazosin was studied in 12 patients with chronic congestive heart failure." | 3.66 | Attenuation of prazosin effect on cardiac output in chronic heart failure. ( Arnold, SB; Baughman, RA; Benet, LZ; Chatterjee, K; Parmley, WW; Ports, TA; Williams, RL, 1979) |
| " New drugs for the treatment of severe congestive heart failure include dopamine, which has a selective nonadrenergic dilator effect on the renal vascular bed, and dobutamine, which has potent inotropic effects, lowers the left ventricular filling pressure and does not increase the heart rate or the systemic vascular resistance." | 3.66 | Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure. ( Armstrong, PW, 1979) |
| "The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure." | 3.66 | Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure. ( Arnold, S; Brundage, B; Chatterjee, K; Parmley, W; Ports, TA, 1979) |
| "The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients." | 3.66 | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. ( Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979) |
| "Twelve patients with severe chronic congestive heart failure (CHF) (NYHA class III and IV) resistant to digitalis and diuretics were treated with the postsynaptic alpha-blocking agent prazosin (PZ) (3 to 20 mg/day)." | 3.66 | Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure. ( Bertel, O; Bühler, FR; Burkart, F, 1981) |
| "The acute hemodynamic effects of oral prazosin were investigated in 7 patients with chronic refractory heart failure." | 3.66 | Acute and chronic cardiocirculatory effects of oral prazosin in chronic refractory heart failure. ( Fukaya, T; Hayashi, H; Matsui, E; Niwa, T; Oba, M; Okubo, M; Sassa, H, 1980) |
| "To evaluate whether long-term administration of the oral vasodilator, prazosin, in the ambulatory therapy of chronic refractory congestive heart failure (CHF) results in gradual attentuation of its marked salutary peripheral circulatory relaxing actions, 16 coronary heart failure patients receiving chronic prazosin, 16 mg daily, were assessed for the development of vasodilator tolerance for 12 months." | 3.66 | Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy. ( Awan, NA; DeMaria, AN; Lee, G; Mason, DT, 1981) |
| "In addition to digitalis and diuretics, 10 patients with chronic cardiac failure were treated with prazosin (15 mg/d) over a period of 6 months." | 3.66 | [Prazosin long-term treatment in severe chronic cardiac failure (author's transl)]. ( Bleifeld, W; Hanrath, P; Kuck, KH; Mathey, D; Zehnke, A, 1980) |
| "The long-term efficacy of the new oral vasodilator, prazosin (PZ), was evaluated in nine patients with refractory heart failure due to chronic coronary heart disease." | 3.65 | Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn ( Awan, NA; DeMaria, AN; Mason, DT; Maxwell, KS; Miller, RR; Neumann, A, 1977) |
| "Nine older men with chronic PTSD secondary to military or Holocaust trauma were prescribed the lipophilic alpha-1 adrenergic antagonist prazosin for treatment-resistant trauma-related nightmares." | 2.71 | Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. ( Bonner, LT; Hoff, DJ; Peskind, ER; Raskind, MA, 2003) |
| "Change in overall PTSD severity exclusive of nightmares was estimated by assigning a Clinical Global Impressions-Change scale (CGI-C) score based on chart review." | 2.70 | Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. ( Dobie, DJ; Hoff, DJ; McFall, ME; Peskind, ER; Petrie, EC; Raskind, MA; Rein, RJ; Thompson, C, 2002) |
| "Terazosine was effective for the treatment of CPPS." | 2.70 | Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. ( Eroğlu, M; Gül, O; Ozok, U, 2001) |
| "Such episodes (known as autonomic dysreflexia) are thought to result from the loss of descending baroreflex inhibition and/or plasticity within the spinal cord." | 1.32 | Tail arteries from chronically spinalized rats have potentiated responses to nerve stimulation in vitro. ( Brock, JA; McLachlan, EM; Yeoh, M, 2004) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 1.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "Prazosin is a post-synaptic alpha-blocker which acts on both cardiac preload and afterload." | 1.27 | [Prazosin in the treatment of chronic cardiac insufficiency]. ( Champoud, O; Cribier, A; Letac, B, 1985) |
| "Isosorbide dinitrate was used in 16 patients, nitroglycerin in 36, pratsiol in 24, and captopryl in 20 patients." | 1.27 | [Comparative evaluation of the effectiveness of various peripheral vasodilators in the treatment of cardiac insufficiency]. ( Ageev, FT; Evdokimova, NKh; Mareev, VIu; Mukharliamov, NM; Novikov, SV, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 62 (72.09) | 18.7374 |
| 1990's | 7 (8.14) | 18.2507 |
| 2000's | 14 (16.28) | 29.6817 |
| 2010's | 3 (3.49) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, XY | 2 |
| Luo, SB | 1 |
| Zhang, JY | 1 |
| Meng, ZC | 1 |
| Wang, J | 2 |
| Yan, D | 1 |
| Liang, K | 1 |
| Xu, Z | 1 |
| Yan, S | 1 |
| Li, HZ | 1 |
| Li, HJ | 1 |
| Jiang, MH | 1 |
| Wu, GC | 1 |
| Liu, HL | 1 |
| Wang, L | 1 |
| Liang, P | 1 |
| Yang, W | 1 |
| Zhou, P | 1 |
| Huang, XK | 1 |
| Liu, JW | 1 |
| Chao, WF | 1 |
| Yang, H | 1 |
| Wang, QT | 1 |
| Raskind, MA | 4 |
| Thompson, C | 1 |
| Petrie, EC | 2 |
| Dobie, DJ | 2 |
| Rein, RJ | 1 |
| Hoff, DJ | 2 |
| McFall, ME | 1 |
| Peskind, ER | 4 |
| Li, J | 1 |
| Lu, R | 1 |
| Wang, JM | 1 |
| Cheah, PY | 2 |
| Liong, ML | 2 |
| Yuen, KH | 2 |
| Teh, CL | 2 |
| Khor, T | 2 |
| Yang, JR | 2 |
| Yap, HW | 2 |
| Krieger, JN | 2 |
| Bonner, LT | 1 |
| Yeoh, M | 1 |
| McLachlan, EM | 1 |
| Brock, JA | 1 |
| Minervini, A | 1 |
| Lapini, A | 1 |
| Serni, S | 1 |
| Carini, M | 1 |
| Tual, L | 1 |
| Morel, OE | 1 |
| Favret, F | 1 |
| Fouillit, M | 1 |
| Guernier, C | 1 |
| Buvry, A | 1 |
| Germain, L | 1 |
| Dhonneur, G | 1 |
| Bernaudin, JF | 1 |
| Richalet, JP | 1 |
| Tapp, AM | 1 |
| Kennedy, A | 1 |
| Novikov, SV | 2 |
| Mareev, VIu | 2 |
| Mason, DT | 7 |
| Awan, NA | 6 |
| Joye, JA | 1 |
| Lee, G | 2 |
| DeMaria, AN | 3 |
| Amsterdam, EA | 1 |
| Lui, HK | 1 |
| Froer, KL | 1 |
| Hall, D | 1 |
| Rudolph, W | 1 |
| Szmydt, W | 1 |
| Kaftańska, A | 1 |
| Paradowski, S | 1 |
| Satinsky, JD | 1 |
| Netz, H | 1 |
| Hagel, KJ | 1 |
| Röhner, G | 1 |
| Rautenburg, HW | 1 |
| Shen, LH | 1 |
| Ku, FS | 1 |
| Liu, QS | 1 |
| Guzińska, B | 1 |
| Nartowicz, E | 1 |
| Okamura, K | 1 |
| Takamatsu, T | 1 |
| Koyanagi, T | 1 |
| Sharpe, DN | 1 |
| Coxon, R | 1 |
| Tomov, I | 2 |
| Kaloianova, A | 2 |
| Terzieva, L | 2 |
| Nikolov, G | 2 |
| Elenkova, A | 2 |
| Chatterjee, K | 5 |
| Parmley, WW | 2 |
| Bassand, JP | 1 |
| Becque, O | 1 |
| Berthout, P | 1 |
| Vial, Y | 1 |
| Magnin, D | 1 |
| Bernard, Y | 1 |
| Maurat, JP | 1 |
| Rutishauser, W | 1 |
| Hockings, BE | 1 |
| Cope, GD | 1 |
| Clarke, GM | 1 |
| Taylor, RR | 1 |
| Ihlen, H | 1 |
| Thaulow, E | 1 |
| Kjekshus, J | 1 |
| Forfang, K | 1 |
| Rouleau, JL | 1 |
| Massie, BM | 1 |
| Berkowitz, RL | 1 |
| Gunnar, RM | 1 |
| Hayashi, H | 1 |
| Sassa, H | 1 |
| Oba, M | 1 |
| Fukaya, T | 1 |
| Okubo, M | 1 |
| Niwa, T | 1 |
| Matsui, E | 1 |
| Stein, L | 1 |
| Henry, DP | 1 |
| Weinberger, MH | 1 |
| Kukes, VG | 1 |
| Zisel'man, SB | 1 |
| Shustikova, GB | 1 |
| Rumiantsev, AS | 1 |
| Shagako, EV | 1 |
| Bertel, O | 1 |
| Burkart, F | 1 |
| Bühler, FR | 1 |
| Kuhn, H | 1 |
| Boch, H | 1 |
| Lösse, B | 1 |
| Silke, B | 1 |
| Taylor, SH | 1 |
| Honda, T | 1 |
| Hiramori, K | 1 |
| Haze, K | 1 |
| Saito, M | 1 |
| Fuseno, H | 1 |
| Fukami, K | 1 |
| Umemoto, M | 1 |
| Tanaka, N | 1 |
| Ikeda, M | 1 |
| Bussmann, WD | 2 |
| Cabaniss, CD | 1 |
| Kuck, KH | 1 |
| Hanrath, P | 1 |
| Zehnke, A | 1 |
| Mathey, D | 1 |
| Bleifeld, W | 1 |
| Paterna, S | 1 |
| Martino, S | 1 |
| Ingurgio, NC | 1 |
| Arrostuto, A | 1 |
| Correo, S | 1 |
| Licata, G | 1 |
| Drabick, JJ | 1 |
| Gambel, JM | 1 |
| Mackey, JF | 1 |
| Kontani, H | 1 |
| Hayashi, K | 1 |
| Lee, JZ | 1 |
| Omata, S | 1 |
| Tillig, B | 1 |
| Perkash, I | 1 |
| Constantinou, CE | 1 |
| Kanter, ED | 1 |
| Thompson, CE | 1 |
| Hord, AH | 1 |
| Denson, DD | 1 |
| Stowe, B | 1 |
| Haygood, RM | 1 |
| Gül, O | 1 |
| Eroğlu, M | 1 |
| Ozok, U | 1 |
| Pettinger, WA | 1 |
| Massie, B | 1 |
| Rubin, S | 1 |
| Gelberg, H | 1 |
| Brundage, BH | 1 |
| Ports, TA | 3 |
| Lloyd, EA | 1 |
| Aronow, WS | 1 |
| Danahy, DT | 1 |
| Packer, M | 3 |
| Meller, J | 2 |
| Elkayam, U | 1 |
| Lejemtel, TH | 1 |
| Mathur, M | 1 |
| Ribner, HS | 1 |
| Frishman, WH | 1 |
| Strom, J | 1 |
| Sonnenblick, EH | 1 |
| Arnold, SB | 1 |
| Williams, RL | 1 |
| Baughman, RA | 1 |
| Benet, LZ | 1 |
| Armstrong, PW | 1 |
| Arnold, S | 1 |
| Brundage, B | 1 |
| Parmley, W | 1 |
| Mehta, J | 1 |
| Iacona, M | 1 |
| Pepine, CJ | 1 |
| Conti, CR | 1 |
| Miller, RR | 2 |
| Miller, MP | 1 |
| Specht, K | 1 |
| Vera, Z | 1 |
| Gorlin, R | 1 |
| Herman, MV | 1 |
| Braunwald, E | 1 |
| Maxwell, KS | 1 |
| Neumann, A | 1 |
| Kondratenko, TIa | 1 |
| Kuzina, NV | 1 |
| Zakharova, IV | 1 |
| Leont'ev, AF | 1 |
| Pashkevich, DD | 1 |
| Seniakovich, VM | 1 |
| Aleksandrov, AE | 1 |
| Klochkov, SA | 1 |
| Rowley, KG | 1 |
| Tung, LH | 1 |
| Hodsman, GP | 1 |
| Howes, LG | 1 |
| Jarrott, B | 1 |
| Beart, PM | 1 |
| Louis, WJ | 1 |
| Antani, JA | 1 |
| Antani, NJ | 1 |
| Nanivadekar, AS | 1 |
| Champoud, O | 1 |
| Cribier, A | 1 |
| Letac, B | 1 |
| Medina, N | 1 |
| Yushak, M | 1 |
| Chodosh, S | 1 |
| Tuck, J | 1 |
| Pizzuto, D | 1 |
| McMillan, M | 1 |
| Chernow, B | 1 |
| Roth, BL | 1 |
| Le Pailleur, C | 1 |
| Aumont, MC | 1 |
| Cohen-Solal, A | 1 |
| Gourgon, R | 1 |
| Motté, G | 1 |
| Vacheron, A | 1 |
| Stone, CK | 1 |
| Liang, CS | 1 |
| Imai, N | 1 |
| Sakamoto, S | 1 |
| Sladek, CD | 1 |
| Hood, WB | 1 |
| Westheim, A | 1 |
| Koss, A | 1 |
| Sivertssen, E | 1 |
| Bregman, B | 1 |
| Le Saux, F | 1 |
| Trottier, S | 1 |
| Chauvel, P | 1 |
| Maurin, Y | 1 |
| Jalil, J | 1 |
| Escobar, E | 1 |
| Thumala, A | 1 |
| Domenech, R | 1 |
| Venegas, P | 1 |
| Reifart, N | 1 |
| Schmidt-Moritz, AD | 1 |
| Nadj, M | 1 |
| Kaltenbach, M | 1 |
| Bayliss, J | 1 |
| Norell, MS | 1 |
| Canepa-Anson, R | 1 |
| Reid, C | 1 |
| Poole-Wilson, P | 1 |
| Sutton, G | 1 |
| Mukharliamov, NM | 1 |
| Evdokimova, NKh | 1 |
| Ageev, FT | 1 |
| Vik-Mo, H | 1 |
| Walde, N | 1 |
| Jentoft, H | 1 |
| Halvorsen, FJ | 1 |
| Ogawa, T | 1 |
| Sekiguchi, T | 1 |
| Ishii, M | 1 |
| Sugishita, Y | 1 |
| Ito, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees[NCT00261729] | 210 participants (Anticipated) | Interventional | 2004-07-31 | Completed | |||
| Prazosin for Noncombat Trauma PTSD[NCT00183430] | 20 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to Insufficient Enrollment) | |||
| A Placebo-Controlled Trial of Prazosin vs. Paroxetine in Combat Stress-Related PTSD Nightmares and Sleep Disturbance[NCT00202449] | 59 participants (Actual) | Interventional | 2004-07-31 | Terminated (stopped due to recruitment difficulties) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Item B-2 recurrent distressing dreams of the event is a single item from teh Clinician Administered PTSD Scale (CAPS). The rating consists of two parts: Frequency plus Intensity. Symptom frequency rated 0 to 4. Symptom intensity rated 0 to 4. Frequency plus Intensity ratings equal the total score. The total minimum score = zero. The total maximum score = 8. A higher score is worse; a lower score is better. This outcome measure evaluates the change in score from Baseline to Week 8." (NCT00183430)
Timeframe: Baseline to Week 8
| Intervention | Units on a Scale (Mean) |
|---|---|
| Prazosin | -2.00 |
| Placebo | -1.09 |
Pittsburgh Sleep Quality Index is a self-report questionnaire assessing sleep quality and disturbances over a 1-month time interval. A global score is obtained by summing the seven component subscales (total score range: 0-21). A score of 5 or less indicates good sleep quality. A score of more than 5 indicates poor sleep quality. Change is measured from Baseline to Week 8. (NCT00183430)
Timeframe: Baseline to Week 8
| Intervention | Units on a Scale (Mean) |
|---|---|
| Prazosin | 4 |
| Placebo | 2.09 |
The Clinical Global Impression of Change is a 7-point scale that rates global change compared to baseline (1=markedly improved, 2=moderately improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=moderately worse, 7=markedly worse). The Clinical Global Impression of Change is used to determine the impact of treatment effects on meaningful and distinct change in overall sense of well-being and functioning. This outcome measure evaluates change from Baseline to Week 8. (NCT00183430)
Timeframe: Baseline to Week 8
| Intervention | Units on a Scale (Mean) |
|---|---|
| Prazosin | 2.33 |
| Placebo | 3.27 |
"Item B-2 recurrent distressing dreams of the event is a single item from the Clinician Administered PTSD Scale. The rating consists of two parts: Frequency and Intensity. Symptom frequency rated 0 to 4. Symptom intensity rated 0 to 4. Frequency plus Intensity ratings equal the total score. A higher score is worse; a lower score is better. This outcome measure evaluates the change in score from Baseline to Week 12. Minimum = 0 Maximum = 8" (NCT00202449)
Timeframe: Baseline and Week 12
| Intervention | scale points (Mean) |
|---|---|
| Prazosin | -1.29 |
| Paroxetine | -3.11 |
| Placebo | -2.67 |
The Clinical Global Impression of Change is a 7-point scale that rates global change compared to baseline (1=markedly improved, 2=moderately improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=moderately worse, 7=markedly worse). The CGIC is used to determine the impact of treatment effects on meaningful and distinct change in overall sense of well-being and functioning. This outcome measure evaluates change from baseline to Week 12. (NCT00202449)
Timeframe: Baseline to Week 12
| Intervention | scale points (Mean) |
|---|---|
| Prazosin | 3.14 |
| Paroxetine | 2.11 |
| Placebo | 2.33 |
Pittsburgh Sleep Quality Index is a self-report questionnaire assessing sleep quality and disturbances over a 1-month time interval. A global score is obtained by summing the seven component subscales (total score range: 0-21). A score of 5 or less indicates good sleep quality. A score of more than 5 indicates poor sleep quality. Change is measured from Baseline to Week 12. (NCT00202449)
Timeframe: Baseline to Week 12
| Intervention | scale points (Mean) |
|---|---|
| Prazosin | -2.33 |
| Paroxetine | -6.44 |
| Placebo | -3.33 |
9 reviews available for prazosin and Chronic Disease
| Article | Year |
|---|---|
[Adrenergic alpha-receptor blockaders and direct arteriolar vasodilators in treatment of chronic cardiac insufficiency].
Topics: Adrenergic alpha-Antagonists; Arterioles; Cardiac Output, Low; Chronic Disease; Hemodynamics; Humans | 1983 |
Vasodilator therapy for chronic heart failure.
Topics: Captopril; Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrates; Nitroglyceri | 1980 |
Anti-hypertensive drugs in the pregnant patient.
Topics: Antihypertensive Agents; Chronic Disease; Clonidine; Diazoxide; Diuretics; Female; Fetus; Furosemide | 1980 |
The role of vasodilating agents in the treatment of chronic heart failure.
Topics: Cardiac Output; Chronic Disease; Dobutamine; Heart Failure; Humans; Muscle Contraction; Nitroprussid | 1980 |
Recent advances in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Chronic Disease; Clonidine; Diazoxide; Drug Th | 1977 |
Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.
Topics: Aorta; Cardiac Output; Chronic Disease; Heart; Heart Failure; Heart Ventricles; Hemodynamics; Humans | 1978 |
The use of vasodilator agents in the treatment of heart failure.
Topics: Cardiac Output; Cardiomegaly; Catheterization; Chronic Disease; Coronary Vessels; Dose-Response Rela | 1979 |
Oral vasodilator therapy for chronic heart failure: a plea for caution.
Topics: Cardiac Output; Chronic Disease; Forecasting; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin | 1978 |
Chronic cobalt-induced epilepsy: noradrenaline ionophoresis and adrenoceptor binding studies in the rat cerebral cortex.
Topics: Animals; Cerebral Cortex; Chronic Disease; Clonidine; Cobalt; Dihydroalprenolol; Epilepsy; Iontophor | 1985 |
26 trials available for prazosin and Chronic Disease
| Article | Year |
|---|---|
[Triple acupuncture at the Qugu acupoint as an adjunctive therapy for type-Ⅲ chronic prostatitis: Analysis of short- and long-term clinical effects].
Topics: Acupuncture Points; Acupuncture Therapy; Anti-Bacterial Agents; Chronic Disease; Chronic Pain; Combi | 2017 |
A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Chronic Disease; Drug Therapy, Combination; Huma | 2016 |
[Retrospective analysis of the combined therapy of terazosin with chlormezanone for chronic prostatitis/chronic pelvic pain syndrome].
Topics: Adult; Chlormezanone; Chronic Disease; Drug Therapy, Combination; Humans; Male; Middle Aged; Pain Me | 2009 |
[Dexketoprofen trometamol in the treatment of chronic prostatitis/chronic pelvic pain syndrome].
Topics: Adult; Chronic Disease; Humans; Indomethacin; Ketoprofen; Male; Pelvic Pain; Prazosin; Prostatitis; | 2009 |
[Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction].
Topics: Adult; Capsules; Chronic Disease; Drugs, Chinese Herbal; Erectile Dysfunction; Humans; Levofloxacin; | 2012 |
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged; | 2002 |
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged; | 2002 |
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged; | 2002 |
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged; | 2002 |
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged; | 2002 |
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged; | 2002 |
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged; | 2002 |
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged; | 2002 |
Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Combat Disorders; Dreams; Humans; Male; Middle Aged; | 2002 |
[Treatment of external RF hyperthermia combining with alpha 1-adrenergic receptor blocker for patients with prostatodynia and chronic non-bacterial prostatitis].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Combi | 2002 |
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Humans; Male; Middle Aged; Pelvic Pain; Prazos | 2003 |
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug | 2003 |
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug | 2003 |
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug | 2003 |
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug | 2003 |
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug | 2003 |
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug | 2003 |
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug | 2003 |
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug | 2003 |
Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chronic Disease; Dreams; Drug | 2003 |
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Adrenergic alpha-Antagonists; Adult; Chronic Disease; Double-Blind Method; Follow-Up Studies; Humans | 2004 |
[Clinical and polycardiographic evaluation of prazosin in the treatment of chronic congestive heart failure].
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Heart Failure; Heart Function Tests; | 1984 |
Prazosin and captopril in chronic heart failure: comparison of acute haemodynamic and hormonal effects.
Topics: Aged; Aldosterone; Blood Pressure; Captopril; Chronic Disease; Clinical Trials as Topic; Coronary Di | 1982 |
[Treatment of chronic congestive failure with vasodilators (acute trial with prazosin and erythrityl tetranitrate)].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Clinical Trials as Topic; Erythrityl T | 1982 |
Prazosin in the treatment of severe chronic congestive cardiac failure.
Topics: Adult; Aged; Chronic Disease; Echocardiography; Follow-Up Studies; Heart Failure; Hemodynamics; Huma | 1980 |
Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure.
Topics: Aged; Chronic Disease; Clinical Trials as Topic; Drug Tolerance; Epinephrine; Female; Heart Failure; | 1981 |
[Vasodilator treatment of chronic heart failure: a chronic double-blind trial with prazosin and erythrityl tetranitrate].
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Erythrityl Tetranitrate; Female; Hea | 1981 |
[The effects of terazosin hydrochloride and buflomedil in patients with hemicrania without aura].
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Drug Therapy, Combination; Female; | 1994 |
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity; | 2000 |
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity; | 2000 |
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity; | 2000 |
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity; | 2000 |
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity; | 2000 |
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity; | 2000 |
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity; | 2000 |
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity; | 2000 |
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity; | 2000 |
Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Humans; Male; Middle Aged; Prazosi | 2001 |
Efficacy of trimazosin and prazosin therapy on cardiac and exercise performance in outpatients with chronic congestive heart failure.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Dou | 1978 |
[Adrenergic receptors in the liver parenchyma in children with chronic hepatitis].
Topics: Adolescent; Binding Sites; Child; Child, Preschool; Chronic Disease; Dihydroalprenolol; Hepatitis; H | 1992 |
Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Drug Tolerance | 1986 |
Prazosin in hypertensive patients with chronic bronchitis and asthma: a brief report.
Topics: Asthma; Blood Pressure; Bronchitis; Chronic Disease; Forced Expiratory Volume; Humans; Hypertension; | 1989 |
Hemodynamic effects at rest and during exercise in long-term treatment with prazosin in chronic congestive heart failure.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Heart Failure; | 1986 |
[Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year].
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Heart Failure; Heart Va | 1985 |
Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin.
Topics: Aged; Captopril; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; F | 1985 |
51 other studies available for prazosin and Chronic Disease
| Article | Year |
|---|---|
Tail arteries from chronically spinalized rats have potentiated responses to nerve stimulation in vitro.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Arteries; Autonomic Dysreflexia; C | 2004 |
Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Chronic Disease; Humans; Male; Pelvic Pain; Prazosin; Prostatitis; Syndrome; Time Factors | 2005 |
Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Hypertrop | 2006 |
Beneficial effects of prazosin for visual hallucinations associated with chronic cocaine abuse.
Topics: Adrenergic alpha-Antagonists; Chronic Disease; Cocaine-Related Disorders; Crack Cocaine; Hallucinati | 2006 |
Treatment of acute and chronic congestive heart failure by vasodilator-afterload reduction.
Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Cardiac Output; Chronic Disease; Diastole; H | 1980 |
Effects of alpha-receptor blockade with prazosin in advanced chronic congestive heart failure.
Topics: Chronic Disease; Heart Failure; Hemodynamics; Humans; Prazosin; Quinazolines; Receptors, Adrenergic, | 1983 |
[Captopril in chronic congestive heart failure--dose-effect behavior and comparison with prazosin].
Topics: Adult; Aged; Captopril; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 1983 |
Chronic heart failure in the elderly: vasodilator therapy.
Topics: Aged; Blood Pressure; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Humans; Hydralazine | 1983 |
Prazosin for refractory cardiac failure in children.
Topics: Adolescent; Child; Child, Preschool; Chronic Disease; Heart Failure; Humans; Infant; Male; Prazosin; | 1984 |
[Hemodynamic effects and clinical observations on prazosin in treating chronic refractory congestive heart failure].
Topics: Adult; Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazos | 1984 |
[Effect of vasodilator treatment of chronic circulatory insufficiency on various polycardiographic parameters].
Topics: Chronic Disease; Drug Therapy, Combination; Female; Heart; Heart Failure; Heart Function Tests; Huma | 1983 |
[Management of chronic spinal cord injury patients with prazosin].
Topics: Adult; Chronic Disease; Female; Humans; Male; Middle Aged; Prazosin; Quinazolines; Spinal Cord Injur | 1983 |
[Hemodynamic effects of prazosin in chronic congestive heart failure].
Topics: Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin; Qui | 1980 |
A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Hydralazine; N | 1983 |
Loss of prazosin effect in severe chronic CHF.
Topics: Adult; Aged; Bed Rest; Chronic Disease; Drug Tolerance; Echocardiography; Female; Heart Failure; Hem | 1981 |
Hydralazine in chronic CHF.
Topics: Administration, Oral; Aortic Valve Insufficiency; Cardiac Output; Chronic Disease; Drug Therapy, Com | 1981 |
Acute and chronic cardiocirculatory effects of oral prazosin in chronic refractory heart failure.
Topics: Administration, Oral; Aged; Blood Pressure; Chronic Disease; Female; Heart Failure; Heart Rate; Hemo | 1980 |
[Use of the new hypotensive agent Minipress (prazosin hydrochloride].
Topics: Adult; Antihypertensive Agents; Chronic Disease; Drug Evaluation; Female; Hemodynamics; Humans; Hype | 1982 |
Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure.
Topics: Aged; Chronic Disease; Dizziness; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pr | 1981 |
Ambulatory prazosin treatment of chronic congestive heart failure: development of late tolerance reversible by higher dosage and interrupted substitution therapy.
Topics: Administration, Oral; Ambulatory Care; Chronic Disease; Drug Tolerance; Forearm; Heart Failure; Hemo | 1981 |
Oral vasodilator therapy with prazosin in severe congestive heart failure.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Chronic Disease; Heart Failure; Hemodynamics; | 1981 |
[Chronic administration of prazosin in patients with congestive cardiomyopathy (author's transl)].
Topics: Adult; Chronic Disease; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Male; Middle | 1981 |
Pharmacokinetic and haemodynamic studies with prazosin in chronic heart failure.
Topics: Aged; Blood Pressure; Chronic Disease; Coronary Disease; Electrocardiography; Exercise Test; Female; | 1981 |
[The effects of prazosin in patients with chronic refractory heart failure-acute hemodynamic effects of oral prazosin and long-term therapy (author's transl)].
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Mal | 1981 |
[Acute and chronic treatment of chronic cardiac insufficiency with nitrates or prazosin respectively].
Topics: Acute Disease; Chronic Disease; Heart Failure; Humans; Nitrates; Prazosin; Quinazolines | 1981 |
Vasodilator therapy of chronic congestive heart failure.
Topics: Ambulatory Care; Chronic Disease; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; Quinazolin | 1980 |
[Prazosin long-term treatment in severe chronic cardiac failure (author's transl)].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Digitalis Glycosides; Diuretics; Drug | 1980 |
Prostatodynia in United Nations peacekeeping forces in Haiti.
Topics: Abscess; Adrenergic alpha-Antagonists; Adult; Age Factors; Anti-Bacterial Agents; Chronic Disease; C | 1997 |
Urinary bladder response to hypogastric nerve stimulation after bilateral resection of the pelvic nerve or spinal cord injury in rats.
Topics: Animals; Atropine; Chronic Disease; Electric Stimulation; Hexamethonium; Hypogastric Plexus; Nicotin | 1997 |
Chronology and urodynamic characterization of micturition in neurohormonally induced experimental prostate growth in the rat.
Topics: Adrenergic alpha-Antagonists; Animals; Chronic Disease; Dihydrotestosterone; Disease Models, Animal; | 1998 |
alpha-1 and alpha-2 Adrenergic antagonists relieve thermal hyperalgesia in experimental mononeuropathy from chronic constriction injury.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-A | 2001 |
Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Heart Ventricles; Hemodynamics; Humans; H | 1978 |
Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Dose-Response Re | 1979 |
Attenuation of prazosin effect on cardiac output in chronic heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Drug Administration Schedule; Female; | 1979 |
Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.
Topics: Chronic Disease; Dobutamine; Dopamine; Heart; Heart Failure; Hemodynamics; Humans; Hydralazine; Moni | 1979 |
Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.
Topics: Adult; Aged; Cardiac Output; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazi | 1979 |
Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure.
Topics: Adult; Aged; Chronic Disease; Ferricyanides; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; | 1979 |
Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output.
Topics: Acute Disease; Arteries; Cardiac Output; Chronic Disease; Electrocardiography; Forearm; Heart Failur | 1978 |
Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.
Topics: Aged; Chronic Disease; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Middle | 1979 |
Vasodilator therapy--a physiologic approach to the treatment of heart failure.
Topics: Administration, Oral; Advertising; Chronic Disease; Heart Failure; Hemodynamics; Humans; Prazosin; Q | 1977 |
Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Blood Pressure; Cardiac Output; Chronic Disease; | 1977 |
Altered alpha 1-adrenoceptor-mediated responses in atria of rats with chronic left ventricular infarction.
Topics: Animals; Chronic Disease; Female; Heart; Heart Rate; Inositol Phosphates; Male; Myocardial Contracti | 1991 |
Prazosin in chronic congestive heart failure due to ischemic heart disease.
Topics: Aged; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up | 1991 |
[Prazosin in the treatment of chronic cardiac insufficiency].
Topics: Adrenergic alpha-Antagonists; Arterioles; Cardiac Output; Chronic Disease; Heart Failure; Humans; Mi | 1985 |
Hepatic alpha 1-adrenergic receptor alteration in a rat model of chronic sepsis.
Topics: Animals; Bacterial Infections; Chronic Disease; Dihydroergotoxine; Disease Models, Animal; Glucose; | 1986 |
[Value of early vasodilator treatment with prazosin in chronic cardiac insufficiency].
Topics: Adult; Aged; Chronic Disease; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Male | 1987 |
Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure.
Topics: Animals; Arginine Vasopressin; Cardiac Output; Chronic Disease; Dogs; Epinephrine; Heart Failure; He | 1988 |
[Vasodilator agents in chronic asymptomatic aortic insufficiency: echocardiographic study].
Topics: Adult; Aged; Aortic Valve Insufficiency; Captopril; Chronic Disease; Echocardiography; Female; Hemod | 1985 |
[Comparative evaluation of the effectiveness of various peripheral vasodilators in the treatment of cardiac insufficiency].
Topics: Administration, Oral; Adolescent; Adult; Captopril; Chronic Disease; Female; Heart Failure; Hemodyna | 1985 |
Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale.
Topics: Administration, Oral; Aged; Carbon Dioxide; Chronic Disease; Female; Hemodynamics; Humans; Hypertens | 1985 |
[Correlations between resting hemodynamics and exercise tolerance before and after prazosin therapy in patients with chronic congestive heart failure].
Topics: Adult; Aged; Chronic Disease; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Midd | 1985 |